The clinical significance of anticardiolipin antibody levels in patients with acute myocardial infarction: a regional study

Basit Öğe Kaydı
dc.contributor.authorErtas, Faruk
dc.contributor.authorCan, Oznur
dc.contributor.authorAcet, Halit
dc.contributor.authorOzbakkaloglu, Mert
dc.date.accessioned2024-04-24T17:24:54Z
dc.date.available2024-04-24T17:24:54Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractIntroduction: Acute myocardial infarction (AMI) will probably remain the most important cause of death over the next decades. Traditional risk factors of atherosclerosis could not exactly explain the development of acute coronary events such as AMI. Antiphospholipid antibody syndrome is a disorder characterized by the development of arterial and venous thrombosis. Aim: In this study, we investigated the relations between acute myocardial infarction and anti-phospholipid antibody syndrome in our population representing Aegean Region people characteristics. Material and methods: One hundred patients with acute myocardial infarction were consecutively included in the study (group I) and one hundred age and sex matched people with similar risk factors were enrolled in the study as a control group (group II). Anticardiolipin antibody (aCL) IgM and IgG levels were measured in the two groups. Levels of aCL IgG >= 48 U/ml and/or aCL IgM >= 44 U/ml were accepted as positive and significant. Results: In patients with acute myocardial infarction, 5 patients (5%) had positive IgM levels and 8 patients (8%) were found to have positive IgG levels. All cases in the control group had negative aCL IgM and IgG antibody levels. These results were accepted as significant for both aCL antibodies between patients and controls (p < 0.001). Conclusions: We concluded that aCL antibody levels are also higher in a small proportion of patients with acute myocardial infarction than controls in our region, also, and these results suggest that there may be an immune stimulus in the pathogenesis of acute coronary events.en_US
dc.identifier.doi10.5114/pwki.2013.38859
dc.identifier.endpage331en_US
dc.identifier.issn1734-9338
dc.identifier.issn1897-4295
dc.identifier.issue4en_US
dc.identifier.pmid24570747
dc.identifier.scopus2-s2.0-84890901497
dc.identifier.scopusqualityQ3
dc.identifier.startpage328en_US
dc.identifier.urihttps://doi.org/10.5114/pwki.2013.38859
dc.identifier.urihttps://hdl.handle.net/11468/19873
dc.identifier.volume9en_US
dc.identifier.wosWOS:000327688400002
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTermedia Publishing House Ltden_US
dc.relation.ispartofPostepy W Kardiologii Interwencyjnej
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAcute Coronary Syndromeen_US
dc.subjectAnticardiolipin Antibodiesen_US
dc.subjectAntiphospholipid Syndromeen_US
dc.subjectThrombosisen_US
dc.titleThe clinical significance of anticardiolipin antibody levels in patients with acute myocardial infarction: a regional studyen_US
dc.titleThe clinical significance of anticardiolipin antibody levels in patients with acute myocardial infarction: a regional study
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu